HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Accepted manuscript (PDF) All Versions of this Article: ERC-08-0301v1 16/2/585    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Durante, C. Articles by Baudin, E. Search for Related Content PubMed PubMed Citation Articles by Durante, C. Articles by Baudin, E.

C Durante, Clinical Sciences, University of Rome , Rome, 00161, Italy
H Boukheris, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, United States
C Dromain, Institut Gustave-Roussy, Villejuif, France
P Duvillard, Institut Gustave-Roussy, Villejuif, France
S Leboulleux, Institut Gustave-Roussy, Villejuif, France
D Elias, Institut Gustave-Roussy, Villejuif, France
T de Baere, Institut Gustave-Roussy, Villejuif, France
D Malka, Institut Gustave-Roussy, Villejuif, France
J Lumbroso, Institut Gustave-Roussy, Villejuif, France
J Guigay, Institut Gustave-Roussy, Villejuif, France
M Schlumberger, Institut Gustave-Roussy, Villejuif, France
M Ducreux, Institut Gustave-Roussy, Villejuif, France
E Baudin, Institut Gustave-Roussy, Villejuif, France

Correspondence: Cosimo Durante, Email: cosimo.durante{at}uniroma1.it

Abstract

Survival of metastatic gastroenteropancreatic well differentiated endocrine carcinoma (GEP WDEC) is not well-characterized. We evaluated the long term outcome and prognostic factors for survival in 118 patients with distant metastases from GEP WDEC. Inclusion criteria were (1) pathological review by a single pathologist according to current WHO criteria, (2) absence of previous therapy apart from surgery, (3) complete morphological evaluation within 3 months including somatostatin receptor scintigraphy, and (4) follow-up at Gustave-Roussy Institute until death or study's end. Clinical, biological marker and pathological parameters were analyzed in univariate and multivariate statistical models. Survival after the first complete imaging work-up of the metastatic disease was determined using Kaplan-Meier method. Overall survival 5 years after the diagnosis of metastatic disease was 54%. In multivariate analysis, age (Hazard Ratio: 1.05, 95%CI: 1.01-1.08, p=0.01), the number of liver metastases (Hazard Ratio: 3.4, 95%CI: 1.4-8.3, p=0.01), tumor slope (Hazard Ratio: 1.1, 95%CI: 1.0-1.1, p=0.001) and initial surgery (Hazard Ratio: 0.3, 95%CI: 0.1-0.8, p=0.01), were predictive of survival. Five-year survival was 100%, 91% (95%CI, 51% to 98%), 62% (95%CI, 37% to 83%) and 9% (95%CI, 6% to 32%) when patients had 0, 1, 2, 3 or more poor prognostic features respectively. This study enables the stratification of metastatic GEP WDEC patients into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and also to design and interpret clinical trials.